Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches

Nakamura, Shigeo; Ponzoni, Maurilio

doi:10.1016/j.pathol.2019.08.012

Cited by 36 publications

(51 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its oncogenic activity is attributed to overexpression of MALT1, which is an important mediator of activation of the canonical and non-canonical NF-jB pathways. [44][45][46][47][48] Other recurrent translocations, more commonly observed at extra-GI sites, have been reported in <5% of GI MALT lymphomas in most published series. They include the t(14;18)(q32;q21)/IGH-MALT1, t(1;14)(p22;q32)/IGH-BCL10, and t(3;14) (p14.1;q32)/IGH-FOXP1 translocations.…”

Section: Pathological Featuresmentioning

confidence: 99%

“…The most frequent in the GI tract is the t(11;18)(q21;q21) /BIRC3 – MALT1 translocation, found in approximately 25% of gastric and 10–50% of intestinal MALT lymphomas. Its oncogenic activity is attributed to overexpression of MALT1, which is an important mediator of activation of the canonical and non‐canonical NF‐κB pathways 44–48 . Other recurrent translocations, more commonly observed at extra‐GI sites, have been reported in <5% of GI MALT lymphomas in most published series.…”

Section: Small B‐cell Lymphomasmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications

2020

View full text Add to dashboard Cite

Approximately one‐third of extranodal non‐Hodgkin lymphomas involve the gastrointestinal (GI) tract, with the vast majority being diagnosed in the stomach, duodenum, or proximal small intestine. A few entities, especially diffuse large B‐cell lymphoma and extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue, represent the majority of cases. In addition, there are diseases specific to or characteristic of the GI tract, and any type of systemic lymphoma can present in or disseminate to these organs. The recent advances in the genetic and molecular characterisation of lymphoid neoplasms have translated into notable changes in the classification of primary GI T‐cell neoplasms and the recommended diagnostic approach to aggressive B‐cell tumours. In many instances, diagnoses rely on morphology and immunophenotype, but there is an increasing need to incorporate molecular genetic markers. Moreover, it is also important to take into consideration the endoscopic and clinical presentations. This review gives an update on the most recent developments in the pathology and molecular pathology of upper GI lymphoproliferative diseases.

show abstract

Section: Pathological Featuresmentioning

confidence: 99%

Section: Small B‐cell Lymphomasmentioning

confidence: 99%

Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications

2020

View full text Add to dashboard Cite

show abstract

“…The pathological diagnoses were: MZL-MALT in 5/13 (38.4%), LymphoEpithelial SialAdenitis (LESA) in 1/13 (7.7%), diffuse lymphocytic sialadenitis lacking LELs in 1/13 (7.7%), 3/13 (23.1%) other speci c entities (one granulomatous sialadenitis consistent with sarcoidosis, one IgG4-related disease and one chronic sclerosing sialadenitis) ( Fig. 3) (3,4,26,27). Other miscellaneous entities were identi ed in 3/13 (23.1%) patients (Table 2).…”

Section: Us-guided Cnb Casesmentioning

confidence: 99%

Ultrasound-guided core needle biopsy compared to open biopsy: a new diagnostic approach to major salivary gland enlargement in Sjögren’s syndrome

Zabotti

Callegher

Lorenzon

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Persistent (≥2 months) major salivary gland (SG) enlargement in primary Sjögren's syndrome (pSS) patients is a well-known sign of possible involvement by B-cell lymphoma. The study aimed to evaluate the diagnostic accuracy and safety of ultrasound-guided core needle biopsy (US-guided CNB) of major SGs in comparison to open surgical biopsy. Methods Prospective pSS patients (cases) with clinically persistent SG enlargement underwent US-guided CNB, and were compared to retrospective pSS patients (controls) submitted to open surgical biopsy. The features analyzed were pre-biopsy clinical and laboratory findings, biopsy-related complications (reported by the patient with a questionnaire and clinically verified), adequacy of the material for histology and diagnosis rendered. Results Thirteen cases underwent US-guided CNB: in 9/13 biopsy was performed on the parotid and in 4/13 on the submandibular gland. Sufficient material was obtained for pathological diagnosis in all samples. The final diagnoses were: 5/13 (38.5%) B-cell lymphoma, 1/13 (7.7%) lympho-epithelial sialadenitis, 4/13 (30.7%) other sialadenitis (granulomatous consistent with sarcoidosis, IgG4-related disease, chronic sclerosing, diffuse chronic) and 3/13 (23.1%) miscellaneous lesions. Thirteen controls underwent open surgical biopsy of the parotid, in one inadequate material was obtained, in 12 (92.3%) the pathologic diagnoses were: 4/12 (33.3%) B-cell lymphoma, 2/12 (16.7%) lympho-epithelial sialadenitis, 4/12 (33.3%) uncertain lymphoproliferative lesions, 2/12 (16.7%) miscellaneous lesions. 6/13 (46.1%) cases reported 6 transient complications, and 12/13 (92.3%) controls 2 persistent and 14 transient complications. Conclusion US-guided CNB represents a novel, clinically relevant and safe approach to the management of pSS patients with parotid or submandibular persistent enlargement.

show abstract

“…This work is intended to support the surgical pathology practice. For a detailed discussion of the clinical and pathophysiological features of each entity, the reader is referred to the many excellent reviews published on this topic 5-10 .…”

Section: Introduction and Clinical Relevancementioning

confidence: 99%

Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach

Pizzi

Sabattini²,

Parente

et al. 2020

Pathologica

View full text Add to dashboard Cite

Summary The gastrointestinal tract (GI) is the primary site of lymphoproliferative lesions, spanning from reactive lymphoid hyperplasia to overt lymphoma. The diagnosis of these diseases is challenging and an integrated approach based on clinical, morphological, immunohistochemical and molecular data is needed. To reach to confident conclusions, a stepwise approach is highly recommended. Histological evaluation should first assess the benign versus neoplastic nature of a given lymphoid infiltrate. Morphological and phenotypic analyses should then be applied to get to a definite diagnosis. This review addresses the key histological features and diagnostic workup of the most common GI non-Hodgkin lymphomas (NHLs). Differential diagnoses and possible pitfalls are discussed by considering distinct groups of lesions ( i.e. small to medium B-cell NHLs; medium to large B-cell NHLs; T-cell NHLs; and mimickers of Hodgkin lymphoma). The key clinical and epidemiological features of each entity are also described.

show abstract

Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches

Cited by 36 publications

References 150 publications

Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications

Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications

Ultrasound-guided core needle biopsy compared to open biopsy: a new diagnostic approach to major salivary gland enlargement in Sjögren’s syndrome

Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach

Contact Info

Product

Resources

About